Introduction
============

Near-triploidy/tetraploidy is a rare cytogenetic abnormality in acute leukemia (AL), often involving numerical and structural abnormalities.[@b1-cmar-11-1559]--[@b3-cmar-11-1559] The near-triploidy karyotype often originates from a duplication of low hypodiploid karyotype in acute lymphoblas-tic leukemia (ALL) and is associated with poor prognosis.[@b4-cmar-11-1559] However, near-triploidy karyotype is frequently misinterpreted as high hyperdiploid karyotype with favorable prognosis.[@b5-cmar-11-1559],[@b6-cmar-11-1559] So far, only limited data are available because of the low incidence of this ALL subset, affecting only 1% of B lineage ALL.[@b7-cmar-11-1559] However, near-tetraploidy in acute myelocytic leukemia (AML) is usually divided into two categories: primary and secondary.[@b8-cmar-11-1559] Primary near-tetraploidy AML originates from pluripotent myeloid progenitor cells, and most metaphase cells demonstrate near-tetraploidy karyotypes. Secondary near-tetraploidy AML originates from further differentiated myeloid precursor cells and is often associated with a duplication of abnormal chromosomes.[@b9-cmar-11-1559] Xue et al reported six cases of secondary near-tetraploidy AML. This rare secondary near-tetraploidy was characterized by double t(8;21) leukemia, which might be associated with poor prognosis.[@b10-cmar-11-1559],[@b11-cmar-11-1559]

Unfortunately, the karyotype of this entity is complex and the precise numerical and structural abnormalities are difficult to distinguish by conventional karyotype analysis. Thus, in most routine clinical diagnostic laboratories, fluorescence in situ hybridization (FISH) is the gold standard to overcome this limitation.[@b12-cmar-11-1559],[@b13-cmar-11-1559]

To better characterize this entity, we analyzed 10 patients with near-triploidy/tetraploidy-AL by FISH. Through inter/ metaphase FISH, we identified a complex karyotype with multiple chromosomal abnormalities and marker chromosomes. In addition, FISH detected a small percentage of genomic variations. Overall, FISH can help identify the mechanisms involved in forming such karyotypes and offer information on the prognostic impact of gene alterations and chromosomal abnormalities.

Patients and methods
====================

Patients
--------

We searched the database of the clinical cytogenetics laboratory at the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University during the years 2006 and 2018. A total of 10 cases with near-triploidy/ tetraploidy-AL were enrolled. We reviewed electronic records of patients' data, including performance status, treatment regimen, response to induction therapy, and survival. The ethics committee of the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University had approved our data collection and sample analysis. All patients completed the informed written consent (informed written consent was completed by a parent or guardian in regards to patients under the age of 18 years) in accordance with the Declaration of Helsinki.

Morphology and flow cytometric immunophenotyping
------------------------------------------------

Bone marrow (BM) aspirate smears were reviewed in all cases. Cases were classified according to French-- American-- British criteria. Cell surface antigens were detected by flow cytometry (FACSC anto™ II; BD, Franklin Lakes, NJ, USA) and further analyzed by extended panels designed to characterize AL according to the methods described previously.[@b14-cmar-11-1559]--[@b16-cmar-11-1559]

Conventional karyotyping
------------------------

BM cells were cultivated for 24--48 hours without mitogen stimulation and harvested for chromosomal examination in a standard way. At least 20 metaphases R-banded by the Giemsa stain were examined, and the International System for Human Cytogenetic Nomenclature (2009) was used to describe chromosomal abnormalities.

Molecular genetic analysis
--------------------------

### RT-PCR analysis

Total RNA was extracted from the patients' BM cells at the time of diagnosis and relapse. RT-PCR analyses were performed following the manufacturer's instructions. For *PML--RARA* fusion gene, RT-PCR was performed to detect long and short *PML--RARA* chimeric transcripts by using total RNA essentially, as described previously.[@b17-cmar-11-1559] For *AML--ETO*, the primer sequences used was reported elsewhere.[@b18-cmar-11-1559],[@b19-cmar-11-1559]

### Fluorescence in situ hybridization

We used the 19 commercially available probes to detect 10 cases by inter/meta FISH. Interphase signals were evaluated in 200 nuclei of cells. Images were captured by a Nikon 80-A1 fluorescent microscope and analyzed with image analysis software AI.

Statistical analysis
--------------------

All data were analyzed using the SPSS for Windows (ver. 16.0; SPSS Inc.). Overall survival (OS) was measured from the date of diagnosis until the last follow-up or death. *P*≤0.05 was considered to be statistically significant.

Results
=======

Patients
--------

Between 2006 and 2018, a total of 1,031 patients were diagnosed with AL, but only 10 patients (3 females and 7 males) were enrolled in our project (10/1,031). The patients' baseline demographic and clinical features are summarized in [Table 1](#t1-cmar-11-1559){ref-type="table"}. Age ranged from 6 to 88 years, with a median age of 38.3 years. Eight (80%) were adults and two (20%) were children (age \<18 years old). Six patients were classified as AML and the remaining four were ALL. Detailed case descriptions and analysis can be found in [Tables 1](#t1-cmar-11-1559){ref-type="table"} and [2](#t2-cmar-11-1559){ref-type="table"}; [Figures 1](#f1-cmar-11-1559){ref-type="fig"}[](#f2-cmar-11-1559){ref-type="fig"}[](#f3-cmar-11-1559){ref-type="fig"}-[4](#f4-cmar-11-1559){ref-type="fig"}; and [Figures S1--S8](#SD1-cmar-11-1559){ref-type="supplementary-material"}.

Laboratory, morphologic, and immunophenotypic findings
------------------------------------------------------

All patients' laboratory findings are reported in [Table 1](#t1-cmar-11-1559){ref-type="table"}. The median percentage of BM blasts was 69.5% (range, 40%--95.5%). BM aspirates showed active proliferation of leukemic cells and all cases showed large blasts, though some also had admixed blasts ([Figure 1A-1, B, D, E](#f1-cmar-11-1559){ref-type="fig"}). Auer rods and cytoplasmic granules could easily be seen in six AML cases ([Figure 1A](#f1-cmar-11-1559){ref-type="fig"}-[2, C](#f2-cmar-11-1559){ref-type="fig"}).

In AML, leukemic blasts frequently expressed myeloid-associated markers CD13 (5/6), CD33 (5/6), and CD117 (5/6).[@b20-cmar-11-1559],[@b21-cmar-11-1559] Case 7, with AML-M2, expressed not only classical myeloid-associated markers, but also CD19 and CD38 lymphoid-associated markers and CD56 antigen. Case 6 was diagnosed with gastric lymphoma, and immunohisto-chemistry analysis of a biopsy specimen found positivity for CD20, CD45RO, BCL-2, and LCA. About 10 years later, the patient was diagnosed with AML in diploid cells and expressed CD34 and CD117. Upon relapse after 9 months, the immunological analysis of the patient was not acquired. This phenomenon revealed that an AML immunophenotype might be accompanied by nontypical myeloid expression. This condition was also discovered in ALL. Case 3 showed typical myeloid-associated markers of CD13, CD15, and CD33 without any lymphoid-associated markers. Case 4 expressed CD16 and CD56. These findings suggest that immunophenotypic heterogeneity exists in near-triploidy/ tetraploidy-AL.[@b9-cmar-11-1559],[@b22-cmar-11-1559]

Cytogenetics
------------

Karyotypes of all 10 patients are listed in [Table 2](#t2-cmar-11-1559){ref-type="table"}. The chromosome numbers in these cases were within 70--97. A total of three cases demonstrated a coexisting diploid karyotype and three cases presented a coexisting high hypodiploidy (42--45 chromosomes)/low hyperdiploidy (47--49 chromosomes) karyotype. In this cohort, numerical alterations were seen in eight cases, structural alterations in nine cases, and one case (Case 1) showed a non-complex karyotype ([Figure S8](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Two cases with near-triploidy karyotype were both diagnosed with ALL (Case 2 and Case 4), and the remaining eight were near-tetraploidy karyotype. Three cases had lost chromosome 7, and one case had deletion of 7q. Thus, four cases had abnormal chromosome 7 (4/10; [Figure 3A](#f3-cmar-11-1559){ref-type="fig"}; [Figures S1A, S2, S3A, B, D](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Furthermore, two of four cases had concomitantly lost chromosome 13 (2/4) and one of four cases had an extra chromosome 22×2 ([Figure 3A](#f3-cmar-11-1559){ref-type="fig"}; [Figures S1A, S3C](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Case 3 had a tetraploidy karyotype both at diagnosis and relapse, as well as the amplification of 1q and deletion of 8q, respectively ([Figure S4A, B](#SD1-cmar-11-1559){ref-type="supplementary-material"}). In Case 6, diploid clones were detected at first diagnosis, but near-tetraploidy clones were found at relapse, both accompanied by typical t(8;21). Moreover, the karyotype of t(8;21) was also observed in Case 5 and Case 7 ([Figure 2A, B](#f2-cmar-11-1559){ref-type="fig"}; [Figure S5](#SD1-cmar-11-1559){ref-type="supplementary-material"}). The classical t(15;17) was found in Case 10 ([Figure S6A](#SD1-cmar-11-1559){ref-type="supplementary-material"}).

Results of inter/metaphase FISH analysis
----------------------------------------

Inter/metaphase FISH results were obtained in all 10 cases. The details of 19 probes are listed in [Table S1](#SD1-cmar-11-1559){ref-type="supplementary-material"}.

### Translocation and isodicentric findings

We used GLP *RUNX1--RUNX1T1* probes to detect clonal aberrations.[@b23-cmar-11-1559] In AML, a double t(8;21)(q22;q22) trans-location occurred in three patients (30%) by karyotype analysis, but classical t(8;21) was detected in two cases by FISH ([Figures S2](#SD1-cmar-11-1559){ref-type="supplementary-material"} and [S5](#SD1-cmar-11-1559){ref-type="supplementary-material"}). One insertion translocation of ins(21;8)(q22;q24q22) occurred in Case 7, which was further confirmed by GLP *RUNX1--RUNX1T1, ETV6--RUNX1,* and *MYC* probes ([Figure 2C--E](#f2-cmar-11-1559){ref-type="fig"}). Case 10 was a child with acute promyelocytic leukemia (APL), having classical double t(15,17)(q22;q21) translocation by karyotype analysis and FISH ([Figure S6A, B](#SD1-cmar-11-1559){ref-type="supplementary-material"}). RT-PCR analysis again revealed the S-type isoform *PML--RARA* fusion transcript in APL cells. After chemotherapy, the patient presented a normal karyotype of 46, XY, N \[20\], but minimal residual disease continued to be positive for 4 months, followed by maintained continuous complete remission (CCR). Case 9 had isodicentric 11q chromosomes idic (11q), as confirmed by a GLP *MLL* (*KMT2A*) probe (located at 11q23) and an *IGH--CCND1* (located at 14q32/11q13) probe, with the loss chromosomes of 5, 7, and 13 ([Figure 3B](#f3-cmar-11-1559){ref-type="fig"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Case 4 had isodicentric 3q chromosomes idic (3q) confirmed by a GLP *BCL6* probe ([Figure S7A](#SD1-cmar-11-1559){ref-type="supplementary-material"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Case 2 showed 22p+×2 confirmed by using a GSP *EWSR1* dual color break-apart probe (located at 22q12), as shown in [Figure S1B](#SD1-cmar-11-1559){ref-type="supplementary-material"}. Combing of the karyotype with amplifications of *RUNX1T1* and *MYC* genes identified two 8q amplifications on 22 p ([Figure S1C](#SD1-cmar-11-1559){ref-type="supplementary-material"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Case 3 demonstrated *IGH* rearrangement at diagnosis and relapse. Moreover, the GLP *IGH* probe displayed one fusion, two red and two green signals (1F2O2G) in a diploid clone, and 2F2O2G in a tetraploid clone, further confirmed by GSP *IGH--CCND3* ([Figure S4C, D](#SD1-cmar-11-1559){ref-type="supplementary-material"}). The metaphase FISH indicated that the *IGH* gene translocated to 6 p (distal CCND3) and there was obviously some distance between the *IGH* and *CCND3* genes, with no fusion gene of the *IGH--CCND3* genes ([Figure S4D](#SD1-cmar-11-1559){ref-type="supplementary-material"}).

### Identification of gene change

A complex karyotype is the existence of three or more clonal aberrations, and this was detected in 80% (8/10) of patients by FISH in our study. Through the FISH technique, a *TP53* deletion was found in three cases: two in ALL and one in AML (3/10). Homologous deletion of *P16* was found in Case 3, accompanied by the absence of *TP53* ([Figure S4E](#SD1-cmar-11-1559){ref-type="supplementary-material"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}). Moreover, *P16* amplification on the 9 p locus was detected in Case 4 ([Figure S7B, C](#SD1-cmar-11-1559){ref-type="supplementary-material"}).

We observed the apparent phenomenon of *BCL6* and *MYC* genes' amplification and deletion. *BCL6* was deleted in four cases and amplified in three cases. Furthermore, *MYC* was deleted in two cases and amplified in two cases. Three cases had *MYC* deletion, as well as amplification ([Figure 4](#f4-cmar-11-1559){ref-type="fig"}). Case 10 had classical double t(15;17), and also 3F (10%) and 5F (5%) signals in the *MYC* gene were found in this patient. Moreover, *IGH* and *PDGFRB* genes were apparently commonly seen abnormalities in our study in near-triploidy/ tetraploidy-AL ([Figure 4](#f4-cmar-11-1559){ref-type="fig"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}).

Follow-up and outcomes
----------------------

Treatment, response, and outcome data are presented in [Table 1](#t1-cmar-11-1559){ref-type="table"}. Median OS was 11 months. All patients received chemotherapy. Of the ALL patients, Case 1 was an 8-year-old child with a history of thalassemia for 3 years, with detection of mutation in the α-globulin (WS site) and β-globulin (CD117 site). Then the patient developed near-tetraploidy ALL. In addition, the patient responded poorly to chemotherapy, presenting with apparent myelosuppression, drug-induced hepatitis, and secondary infection. After treatment lasting 3 months, the patient's disease ameliorated, and later, the patient received allogeneic hematopoietic stem cell transplant (HSCT), but relapsed after 9 months and finally died of infection. Cases 2, 3, and 4 had a shorter survival period (range, 3--6 months). Especially, Case 3 initially achieved remission after Vincristine, [l]{.smallcaps}-[asparaginase]{.smallcaps}, [and]{.smallcaps} P[rednisone]{.smallcaps} (VLP) with Cytarbine and Darubicin (IA) treatment, but then relapsed quickly. Therefore, we changed the treatment regimen to IA and Mitoxantrone (Novantrone) and Ara-C (NA), but failed to elicit a response. Case 4 was an 88-year-old patient, so a regimen suitable for elderly women was used, but the patient did not respond.

Of the AML patients, cases 5, 6, 7, and 8 relapsed after chemotherapy. Cases 5 and 8 achieved remission after treatment for 6 months. However, 4--5 months later, both patients relapsed, were refractory to treatment, and died of lung infection and intracranial hemorrhage, respectively. Case 6 was diagnosed with AML with a history of postoperative gastric lymphoma for 11 years. The patient received chemotherapy for about 6 months. The patient entered remission and received Chinese medicine. However, 4 months later, relapse occurred and decitabine with Cytarabine, Aclarubicin, and G-CSF were administered, but the patient died of intracranial hemorrhage. Case 7, diagnosed with AML-M2 with ins(21;8)(q22;q24q22), was still alive until the end of follow-up. Despite achieving remission after treatment, the patient relapsed after 7 months. During this period, the *RUNX1--RUNX1T1* gene was persistently positive, so the patient failed to achieve molecular complete remission. Hence, various protocols were used without achieving remission. In addition, Case 6 was primary near-tetraploidy, while Cases 5 and 7 were secondary near-tetraploidy, accompanied by diploid clones,[@b8-cmar-11-1559],[@b11-cmar-11-1559] and Case 9 died of pyemia after 2 months. For Case 10, we administered all-trans retinoic acid (ATRA) treatment. However, the child developed fever and back pain symptoms after 10 days, which was considered to be retinoic acid syndrome (differentiation syndrome). After the child was relieved of his syndrome, we treated him with other chemotherapeutic regimens combined with ATRA. The patient underwent CCR for 34 months and was positive for the S-type isoform of *PML--RARA* at the first diagnosis, but became negative after four rounds of chemotherapy.

Discussion
==========

Because of its rarity, near-triploidy/tetraploidy has been seldom studied. Herein, we have described 10 near-triploidy/ tetraploidy-AL cases with gene alterations and chromosomal abnormalities. Notably, the t(8;21)(q22;q22) is a common chromosomal change in diploid AML accompanied by loss of sex chromosomes, which correlates with a favorable prognosis.[@b24-cmar-11-1559]--[@b26-cmar-11-1559] However, the incidence of t(8;21) is rare in near-tetraploid patients t(8;21)(q22;q22).[@b24-cmar-11-1559],[@b25-cmar-11-1559],[@b27-cmar-11-1559] Herein, we have reported three novel cases (Cases 5, 6, and 7) of near-tetraploidy AML with double t(8;21)(q22;q22). In particular, by using FISH and RT-PCR, Case 7 was first proven to have an insertion translocation of ins(21;8) (q22;q24q22) in diploid and tetraploid cells. Only 14 cases with diploid ins(21;8) have been reported ([Table S3](#SD1-cmar-11-1559){ref-type="supplementary-material"}).[@b28-cmar-11-1559]--[@b30-cmar-11-1559] Furthermore, some reports had revealed that the occurrences of translocation breakpoints near t(9;22) often involve segmental duplications; but whether this also happened in Case 7 is unknown because whole genome sequencing was not performed.[@b31-cmar-11-1559],[@b32-cmar-11-1559] Despite our best efforts, Case 7 did not acquire hematological and cytogenetic remission during follow-up. We screened five genes (*FLT3-ITD*, *CK-kit D816V*, *NPM1 \[exon12\]*, *DNMT3AR882*, and *CEBPA*) and detected a *CK-kit D816V* mutation. We supposed that the *CK-kit D816V* mutation may be associated with poor prognosis.[@b33-cmar-11-1559] Case 8 survived for 12 months with a chromosome 7q deletion and trisomy 22. Case 9 survived for 2 months with *MLL* amplification, which further demonstrated that *MLL* is closely correlated with poor prognosis.

Furthermore, APL in tetraploidy harboring double t(15;17)(q22;q21) is extremely rare, and only 15 cases have been reported.[@b34-cmar-11-1559],[@b35-cmar-11-1559] The majority of cases were Asians. In our present study, we first reported double t(15;17)(q22;q21) in a child (Case 10) with giant and bizarre myeloblasts and faggot cells filled with granules. In reviewing the15 reported cases, 13 patients with APL attained complete remission and responded favorably to ATRA.[@b34-cmar-11-1559],[@b35-cmar-11-1559] Thus, we combined other chemotherapeutic regimens with ATRA to treat this patient. During the 34 months of follow-up, the patient achieved CCR and *PML--RARA* was negative after treatment. Hence, allogeneic HSCT was unnecessary in this case. Interestingly, small ratios of genomic aberrations in the patient were found, thereby suggesting that these genomic changes did not affect his prognosis.

Among the four patients with ALL, Case 1 had thalassemia disease. Although this patient was the only patient to receive HSCT, the patient relapsed and died. From this case, we propose that thalassemia has a potential correlation with disease severity. For Case 3, we found IGH rearrangement and detected a homogeneous deletion of p16 by FISH.[@b36-cmar-11-1559],[@b37-cmar-11-1559] VLP with IA, IA, and NA regimens were used for the treatment of this patient, but they failed to improve prognosis. The survival of cases 2 and 4 was very short, at 6 and 3 months, respectively. Moreover, we observed gene amplification in ALL patients. Thus, we propose that multi-amplification might be a cause of unfavorable prognosis and near-triploidy/tetraploidy karyotype, in particular, is a high-risk factor in ALL.[@b38-cmar-11-1559],[@b39-cmar-11-1559] From these cases, it is clear that further improvement in therapy and study on the origins of ALL are vital.[@b39-cmar-11-1559]

We found deletions, amplifications, translocations, and rearrangements in the 10 patients by inter/metaphase FISH, and also detected a small portion of gene alterations (*BCL6*, *MYC,* and *PDFGRB* genes) and large region chromosome amplifications (1q+, 8q+, \[idic (3q)\], and \[idic (11q)\]), compared with conventional karyotype analysis and microarray. We used FISH to explore how they contributed to the leukemogenic process and demonstrated various different chromosomal and genomic abnormalities ([Figure 4](#f4-cmar-11-1559){ref-type="fig"}; [Table S2](#SD1-cmar-11-1559){ref-type="supplementary-material"}). The phenomenon showed that tetraploidy originated from the missegregation of chromosomes and chromosome instability, as previously reported.[@b40-cmar-11-1559],[@b41-cmar-11-1559]

Conclusion
==========

In summary, the present study clearly showed that near-triploidy/tetraploidy-AL cells may possess distinctive features, not only in morphology and immunophenotypic heterogeneity but also in karyotype instability and in response to therapeutic agents. Hence, a new treatment regimen is urgently needed.
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![BM morphologic features.\
**Notes:** (**A-1**) (Case 7): Blasts are large with multiple and irregular nuclei and large nucleoli; cytoplasm is dark blue and filled with granules and prominent cytoplasmic vacuoles (arrow). Peripheral blood (**A-2**) (Case 7): Auer rod (arrow). (**B**) (Case 9): Blasts are different in size with pleomorphic nuclei and prominent nucleoli. Multinucleate blasts (arrow). (**C**) (Case 10): Blasts are different in size and filled with granules and prominent cytoplasmic pseudopodia. Faggot cell (arrow). (**D**) (Case 3): Atypical large blasts with irregular nuclear outlines and frequent cytoplasmic vacuoles, showing large nuclei and nucleoli. (**E**) (Case 2): Blasts are large with prominent, multiple, and pleomorphic nuclei. Magnification ×1000.\
**Abbreviation:** BM, bone marrow.](cmar-11-1559Fig1){#f1-cmar-11-1559}

![Karyotype and FISH analysis (Case 7).\
**Notes:** Numbers 1--22 represent chromosomes. (**A**) Karyotype of diploidy (R-banding): 46, XY, t (8;21)(q22;q22). 8q-(red arrow) and 21q+ (green arrow). (**B**) Karyotype of tetraploidy (R-banding): 92, XXYY, t(8;21)(q22;q22)×2. 8q-(red arrow) and 21q+ (green arrow). (**C**) FISH analysis with GLP *RUNX1--RUNX1T1* dual color fusion probe (located at 21q22/8q22). Revealing 2F4O4G signals. Two fusions on the end of 21q+, four red signals (red arrow) are on native chromosome 8 and 8q−, two green signals proximal to the centromere of 21q+ (yellow arrow), and two native chromosome 21 (green arrow). (**D**) FISH analysis with GLP C-*MYC* dual color break-apart probe (located at 8q24); the picture displays that 8q24 (*MYC*) (red arrow) had not moved to 21q+. (**E**) FISH analysis with GLP *ETV6--RUNX1* dual color fusion probe (located at 12p13/21q22). Tetraploidy metaphase shows red signals (red arrow) on chromosome 12, and six green signals (green arrow) consist of two on native chromosome 21 and four on 21q+×2. Magnification ×1000.\
**Abbreviation:** FISH, fluorescence in situ hybridization.](cmar-11-1559Fig2){#f2-cmar-11-1559}

![Karyotype and FISH analysis (Case 9).\
**Notes:** Numbers 1 -22 represent chromosomes. (**A**) Karyotype (R-banding): 86, XXYY, −5, --5, --7, I (11q)×2, --13, −13, --18. Red arrow represents isodicentric 11q chromosomes. (**B**) FISH analysis with GLP *MLL* dual color break-apart probe (located at 11q23). The probe confirms two idic (11q) chromosomes (red arrow). Magnification ×1000.\
**Abbreviation:** FISH, fluorescence in situ hybridization.](cmar-11-1559Fig3){#f3-cmar-11-1559}

![Genes change in near-triploid/tetraploid-AL in 10 cases.\
**Abbreviation:** AL, acute leukemia.](cmar-11-1559Fig4){#f4-cmar-11-1559}

###### 

Demographic and clinical features and treatment outcomes in near-triploidy/tetraploidy-AL patients

  Case   Age (years)/ sex   WBC (×10^9^/L)   Hb (g/L)   Platelets (×10^9^/L)   Juvenile cells ratio   Percent blasts   Diagnosis   Immunophenotypic analysis   Treatment           OS (months)
  ------ ------------------ ---------------- ---------- ---------------------- ---------------------- ---------------- ----------- --------------------------- ------------------- -------------
                                                                                                                                                                                   
  1      8/M                40.2             78         30                     0.6                    78.0             ALL (high   CD10 (+), CD19 (+),         VDLP, CAT,          28
                                                                                                                       risk)       CD13 (+), CD33 (+),         HD-MTX, VDLD        
                                                                                                                                   CD34 (+), HLADR (+)                             
  2      45/M               1.99             110        79                     0.06                   78.5             ALL-B       CD34 (+), CD13 (+),         CALLG-2008          6
                                                                                                                                   CD19 (+), CD34 (+),                             
                                                                                                                                   HLADR (+), DT (+),                              
                                                                                                                                   CD79α (−), MPO (−),                             
                                                                                                                                   CD5 (−), CD10 (−),                              
                                                                                                                                   CD14 (−), CD7 (−)                               
  3      49/F               2.0              83         84                     N                      72.5             ALL         CD13 (+), CD15 (+),         VLP + IA, IA, NA    5
                                                                                                                                   CD33 (+), CD15 (+)                              
                                                                                                                                   CD56 (−), MPO (−),                              
                                                                                                                                   CD34 (−), HLADR (−)                             
  4      88/F               1.8              80         28                     N                      45.5             ALL         CD15 (+), CD19(−),          VP-CAM              3
                                                                                                                                   CD16 (+) CD56 (+),                              
                                                                                                                                   CD56 (+), cyCD3 (−)                             
  5      42/M               18.6             36         10                     0.18                   40.0             AML-M2a     CD13 (+), CD15 (+),         IA, FlAG            12
                                                                                                                                   CD33 (+), CD117 (+),                            
                                                                                                                                   MPO (+), HLADR (+),                             
                                                                                                                                   CD34 (+)                                        
  6      59/F               8.1              110        7                      0.51                   95.5             AML-M4      CD34 (+), CD117 (+)         IA, FlAG, HAE,      10
                                                                                                                                                               NAE, decitabine     
                                                                                                                                                               \+ CAG              
  7      23/M               2.1              49         39                     0.22                   59.5             AML-M2      HLADR (+), CD33 (+),        IA, FlAG, HAA,      10 (alive)
                                                                                                                                   CD38 (+), CD56 (+),         cladribine in the   
                                                                                                                                   CD117 (+), MPO (+),         regimen             
                                                                                                                                   CD4 (+), CD13 (+),                              
                                                                                                                                   CD15 (+), CD19 (+),                             
                                                                                                                                   CD64 (+), CD34 (+), CR                          
                                                                                                                                   (−), CK5/6 (−)                                  
  8      28/M               29.96            113        30                     0.92                   91.2             AML-M5a     CD13 (+), CD15 (+),         IA, MD-Ara-C        12
                                                                                                                                   CD33 (+), CD117 (+),                            
                                                                                                                                   MPO (+), HLADR (+),                             
                                                                                                                                   CD34 (+)                                        
  9      35/M               4.06             82         112                    0.12                   50.5             AML         CD13 (+), CD33 (+),         IA                  2
                                                                                                                                   CD117 (+), MPO (+),                             
                                                                                                                                   HLADR (+), CD34 (+)                             
  10     6/M                2.4              70         12                     N                      84.0             APL(M3a)    CD13 (+), CD33 (+),         ATRA + IDA,         34 (alive)
                                                                                                                                   CD117 (+), MPO (+)          ATRA + VP-16 +      
                                                                                                                                                               Ara-C, ATRA +       
                                                                                                                                                               HA, ATRA + VP-      
                                                                                                                                                               16 + HD-Ara-C       

**Abbreviations:** AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CAG, Cytarabine, Aclarubicin, and G-CSF; CALLG-2008, Guideline in China for acute leukemia; CAT, Cyclophosphamide, Ara-C, and Topotecan; F, female; FlAG, Fludarabine, Cytarabine, and G-CSF; HA, Homoharringtonine and Ara-C; HAA, Homoharringtonine, Ara-C, and Aclarubicin; HAE, Homoharringtonine, Ara-C, and Etoposide; Hb, hemoglobin; HD, high dose; IA, Cytarbine and Darubicin; IDA, Idarubicin; M, male; MD, medium dose; MTX, Methotrexate; N, not found; NA, Mitoxantrone (Novantrone) and Ara-C; NAE, Mitoxantrone (Novantrone), Ara-C, and Etoposide; VDLD, Vincristine, Dexamethasone, Levo-asparaginase, and Daunorubicin; VDLP, Vincristine, Daunorubicin, l-asparaginase, and Prednisone; VLP, Vincristine, l-asparaginase, and Prednisone; VP-16, Etoposide; VP-CAM, Vincristine, Prednisone, Cyclophosphamide, Ara-C, 6-MP (6-mercaptopurine); WBC, white blood cell.

###### 

Karyotypes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Karyotype
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------
  1      86−97\<4n\>, XXYY, +X, +1, +5, +8, +10, +12, +16, +20, +21, +22, −Y, −3, −4, −5, −6, −9, −11, −14, −18 \[CP10\]/46, XY, N \[12\]

  2      71−74, XXY, +1, +2, −3, +4, +5, +6, del(6)(q22), + del(6)(q22), −7, +8, +12, −13, +14, +der(15), −17, −19, −20, +21, add(22)(p13), +add(22) (p13) \[CP10\]

  3      1\) 90−92, XXXX, der(1), −1, −8, −21 \[cp10\][a](#tfn2-cmar-11-1559){ref-type="table-fn"}\
         2) 90−92, XXXX, −1, der(1), del(8)(q24), −9 \[cp10\][b](#tfn3-cmar-11-1559){ref-type="table-fn"}

  4      70−76, XX, −X, +1, +2, i(3q), add(9)(p13), +10, add(11)(q23), −12, +17, +18, +19, +20, +21, der(22), +der(22), +marx2 \[CP10\]

  5      90, XX, −Y, −Y, t(8;21)(q22;q22)×2\[CP10\]/45, X, −X, t(8;21)(q22;q22) \[10\]

  6      82−84, XX, −X, −X, del(1)(q21), add(1)(p36), −3, −7, −8, −9, −11, add(5)(q35), −14, −16, −18, t(8;21)(q22;q22)×2 \[CP10\]

  7      92, XXYY, t(8;21)(q22;q22)×2 \[8\]/46, t(8;21)(q22;q22) \[12\]

  8      94, XXYY, del(7)(q31)×2, +22, +22 \[9\]/47, XY, del(7)(q31), +22 \[11\]

  9      83−87, XXYY, −3, −5, −7, −9, −10, −13, −13, −16, −18, i(11q)×2 \[CP10\]/42−43, XY, −3, −5, −13 \[2\]

  10     1\) 92, XXYY, t(15;17)(q22;q21)×2 \[9\]/46, XY, t(15;17)(q22;q21) \[7\][a](#tfn2-cmar-11-1559){ref-type="table-fn"}\
         2) 46, XY,N \[20\][c](#tfn4-cmar-11-1559){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

At the first diagnosis of the disease.

At the first relapse.

Continuous complete remission.
